- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | Lobe Sciences Ltd (2): Lobe Sciences issues 546,206 shares for debt of $11,596 | 2 | Stockwatch | ||
| 17.07. | Lobe Sciences announces debt settlement | - | Seeking Alpha | ||
| 17.07. | Lobe Sciences Ltd. Announces Debt Settlement | 278 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases... ► Artikel lesen | |
| 08.07. | Lobe Sciences Ltd (2): Lobe Sciences receives European unitary patent | 1 | Stockwatch | ||
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 08.07. | Lobe Sciences Ltd.: Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease | 579 | ACCESS Newswire | European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease.Covers... ► Artikel lesen | |
| 18.06. | Lobe Sciences Ltd.: Lobe Sciences Moves Forward with Development of Conjugated Psilocin Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals | 256 | ACCESS Newswire | New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin$6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical... ► Artikel lesen | |
| 03.06. | Lobe Sciences Ltd (2): Lobe Sciences appoints Yao as CFO, EVP | 3 | Stockwatch | ||
| 03.06. | Lobe Sciences Ltd.: Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth | 254 | ACCESS Newswire | Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth.Mr.... ► Artikel lesen | |
| 14.04. | Lobe Sciences Ltd (2): Lobe's Cynaptec arranges $6M (U.S.) private placement | 1 | Stockwatch | ||
| 14.04. | Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin | 176 | ACCESS Newswire | Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studiesUS$20 Million additional option included in Private Placement to fund the Phase 3 clinical... ► Artikel lesen | |
| 05.04. | Lobe Sciences Ltd (2): Lobe Sciences issues notes, shares, RSUs | 2 | Stockwatch | ||
| 05.04. | Lobe Sciences Ltd.: Lobe Sciences Provides Corporate Update | 618 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 4, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a commercial stage biopharmaceutical company focused... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,347 | -0,86 % | BioTech wird zu Gold: Wer schluckt wen oder was? Auf der Liste sind Evotec, BioNxt, Valneva und Formycon! | Der BioTech-Sektor blickt mit Argusaugen auf das Zinsniveau der Notenbanken. Aktuell allerdings scheint die Inflation noch etwas zu hoch, um massive Senkungen zu erwarten. So hat auch die EZB gestern... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| ATAI LIFE SCIENCES | 3,135 | -1,32 % | Atai Life Sciences: NBC-Trader sacken +26% in Kürze ein! | Einmal mehr demonstriert Chefanalyst Maximilian Ruth sein Können und liefert Mitgliedern des No Brainer Club mit der Aktie von Atai Life Sciences satte zweistellige Kursgewinne in Windeseile. Empfehlung... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,046 | +1,55 % | SOL Global Investments Corp.: SOL Global Announces Listing on OTC Markets Under OTCID: SOLCF | Toronto, Ontario--(Newsfile Corp. - July 22, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") is pleased to announce that its common shares... ► Artikel lesen | |
| ENTHEON BIOMEDICAL CORP | 0,054 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Change of Directors | Vancouver, British Columbia--(Newsfile Corp. - April 4, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Harrison Newlands... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,016 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| CYBIN | 6,900 | 0,00 % | Cybin Inc.: Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder | - EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia and will... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: QuickStrip Technology - How Rapid Dose Is Changing The Way We Take Medicine | Toronto, Ontario--(Newsfile Corp. - July 22, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.Founded... ► Artikel lesen | |
| EVOTEC | 7,120 | +4,52 % | EQS-Adhoc: Evotec SE: Evotec passt Umsatzprognose an und bestätigt Gewinnprognose | EQS-Ad-hoc: Evotec SE / Schlagwort(e): Prognoseänderung
Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
21.07.2025 / 11:25 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,255 | 0,00 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| IMMUNOVANT | 18,320 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| QIAGEN | 43,510 | +1,83 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 14,630 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| JANUX THERAPEUTICS | 25,970 | 0,00 % | Raymond James startet Coverage für Janux Therapeutics mit "Outperform"-Rating | ||
| VERVE THERAPEUTICS | 11,130 | 0,00 % | Lilly completes tender offer for Verve Therapeutics shares |
Das Unternehmen LOBE SCIENCES LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +105,71 % bei einem Aktienkurs von 0,036 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.